1334019-92-9

Upstream product

• 116-16-5 1,1,1,3,3,3-hexachloro-propan-2-one 
• 302348-51-2 (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanol 
• 75-44-5 phosgene 

Downstream Products

• 1404094-85-4 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl (2,2-dimethyl-1-(3-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)propoxy)propyl)carbamate 
• 1404094-72-9 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl N-[(2,2-dimethyl-1-(neopentyloxy)propyl)]carbamate 
• 1445994-97-7 C₅₃H₆₁BN₃O₄⁽¹⁺⁾*I^(1-) 
• 1422655-40-0 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl (2-cyanobenzo[d]thiazol-6-yl)carbamate 
• 1610053-89-8 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzylbis(2-chloroethyl)carbamate 
• 1616467-66-3 4-[bis(2-chloroethyl)amino]phenyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl carbonate 

Relevant academic research and scientific papers

Synthesis and Evaluation of Hydrogen Peroxide Sensitive Prodrugs of Methotrexate and Aminopterin for the Treatment of Rheumatoid Arthritis

A series of novel hydrogen peroxide sensitive prodrugs of methotrexate (MTX) and aminopterin (AMT) were synthesized and evaluated for therapeutic efficacy in mice with collagen induced arthritis (CIA) as a model of chronic rheumatoid arthritis (RA). The prodrug strategy selected is based on ROS-labile 4-methylphenylboronic acid promoieties linked to the drugs via a carbamate linkage or a direct C-N bond. Activation under pathophysiological concentrations of H2O2 proved to be effective, and prodrug candidates were selected in agreement with relevant in vitro physicochemical and pharmacokinetic assays. Selected candidates showed moderate to good solubility, high chemical and enzymatic stability, and therapeutic efficacy comparable to the parent drugs in the CIA model. Importantly, the prodrugs displayed the expected safer toxicity profile and increased therapeutic window compared to MTX and AMT while maintaining a comparable therapeutic efficacy, which is highly encouraging for future use in RA patients.

PRODRUGS ACTIVATED BY REACTIVE OXYGEN SPECIES FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES AND CANCER

Prodrugs activated predominantly or exclusively in inflammatory tissue, more particularly prodrugs of methotrexate and derivatives thereof, which are selectively activated by Reactive Oxygen Species (ROS) in inflammatory tissues associated with cancer and inflammatory diseases, as well as method for preparing said prodrugs.

POLYGLYOXYLATES, MANUFACTURE AND USE THEREOF

Self-immolative polymers degrade by an end-to-end depolymerisation mechanism in response to the cleavage of a stabilizing end-cap from the polymer terminus. Examples include homopolymers, mixed polymers including block copolymers, suitable for a variety of applications. A polyglyoxylate can be end-capped or capped with a linker as in a block copolymer.

DETECTION OF HYDROGEN PEROXIDE

The present invention provides compounds of formula (I), (II) or (III) wherein R1and R11are boronic acid or a borate ester useful for detection of hydrogen peroxide and methods of using same.

Versatile approach to α-alkoxy carbamate synthesis and stimulus-responsive alcohol release

A series of α-alkoxy carbamates that cleave under mild conditions to release alcohols has been synthesized through a multicomponent process. The relationship between structural features in these compounds and the rate of alcohol release in the presence of basic hydrogen peroxide has been studied. The preparation of carbamates that cleave under other conditions has been demonstrated.